Indivior Company Profile
✉ Email this page to a colleague
What is the competitive landscape for INDIVIOR, and when can generic versions of INDIVIOR drugs launch?
INDIVIOR has seven approved drugs.
There are twenty-seven US patents protecting INDIVIOR drugs.
There are two hundred and eighty-three patent family members on INDIVIOR drugs in thirty-six countries and one supplementary protection certificate in one country.
Summary for Indivior
International Patents: | 283 |
US Patents: | 27 |
Tradenames: | 6 |
Ingredients: | 5 |
NDAs: | 7 |
Patent Litigation for Indivior: | See patent lawsuits for Indivior |
PTAB Cases with Indivior as patent owner: | See PTAB cases with Indivior as patent owner |
Drugs and US Patents for Indivior
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Indivior | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-003 | Aug 10, 2012 | AB | RX | Yes | No | 9,687,454 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Indivior | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-001 | Jul 27, 2018 | RX | Yes | No | 10,010,612 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Indivior | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | 9,827,241 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Indivior | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-002 | Aug 30, 2010 | AB | RX | Yes | No | 9,687,454 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Indivior | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-003 | Aug 10, 2012 | AB | RX | Yes | No | 8,603,514 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Indivior | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-002 | Aug 30, 2010 | AB | RX | Yes | No | 8,603,514 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Indivior
Paragraph IV (Patent) Challenges for INDIVIOR drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Sublingual Film | 4 mg/1 mg | ➤ Subscribe | 2013-05-14 |
➤ Subscribe | Sublingual Film | 2 mg/0.5 mg and 8 mg/2 mg | ➤ Subscribe | 2012-10-15 |
➤ Subscribe | Sulingual Film | 12 mg/3 mg | ➤ Subscribe | 2014-03-26 |
International Patents for Indivior Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 1799453 | ⤷ Sign Up |
Australia | 2010214780 | ⤷ Sign Up |
Japan | 2013501717 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2007067494 | ⤷ Sign Up |
European Patent Office | 3031445 | ⤷ Sign Up |
Argentina | 056554 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Indivior Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0196132 | 94C0008 | Belgium | ⤷ Sign Up | PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.